URIELLE

Urielle is developing a first-of-its-kind non-invasive urine smart catheter patch for women - an external, wearable alternative to indwelling catheters. It is designed for external use only and aims to deliver safe, dry, and dignified urine management collection with a skin-friendly, low-profile interface suitable for discreet wear. For patients: 🔹Non-invasive care - no internal tubing, less discomfort, and protection of urethral tissue. 🔹Helps reduce the risk of catheter-associated complications, including CAUTIs and skin breakdown. 🔹Supports mobility and independence in the hospital and at home, including long-term and dementia care. 🔹No power source or external vacuum required. For caregivers and hospitals: 🔹Fast, intuitive application by one nurse or by suitable patients in under 30 seconds - no catheterisation training required. 🔹Simplifies hygiene routines, frees nursing time, and supports infection-control goals. 🔹Fits common urine-management workflows and care pathways. For payers and systems: 🔹Preventive approach that can lower avoidable complications and length of stay. 🔹Aligns with antimicrobial-resistance strategies by reducing avoidable antibiotic use. 🔹Targets meaningful savings on catheter-related events. Innovation and progress: Urielle reframes female catheter care from the skin outward - a new device category focused on dignity, safety, and simplicity. The company is relocating to Germany and is advancing toward CE Class IIa conformity under EU MDR. Status and plans: 🔹TRL 2 - aiming for TRL 4 by Q3 2026 with bench and simulated-use validation 🔹EU MDR Class IIa pathway in preparation 🔹IP: USPTO provisional 63/738,648 filed 25 Dec 2024 - FTO opinion issued June 2025 - PCT filing planned Q1 2026 🔹Funding: current raise 200 000 € - seed 2,0 m € targeted for prototyping, Verification & Validation, and pilot adoption Contact: [email protected] · www.urielle.eu

• Employees 1
• Founded 2024